Note we may have some server downtime today and this weekend as we perform some upgrades. Please save a copy of any posts you make during this time in case we have any server trouble. Thank you!
dignan wrote:Another one for pre-clinical - LLDT-8. The thing I'm happy to see here is that this research comes from China. I'd love to see the MS research world harness some more of the immense brain-power in China and India.
(5R)-5-Hydroxytriptolide (LLDT-8 ), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.
J Neuroimmunol. 2006 May 17; [Epub ahead of print]
Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Zhou R, Zhou Y, Dong JR, He PL, Wan H, Li YC, Yang YF, Zuo JP.
Laboratories of Immunopharmacology and Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
A novel triptolide derivative (5R)-5-hydroxytriptolide (LLDT-8 ) has been shown to have potent immunosuppressive activities. Here LLDT-8 was evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS).
LLDT-8 reduced the incidence and severity of EAE, which was associated with the inhibition of the MOG 35-55 lymphocyte recall response, anti-MOG 35-55 T cell responses, interleukin (IL)-2 and interferon (IFN)-gamma production. In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-gamma production stimulated with anti-CD3/28.
These findings highlight the fact that LLDT-8 prevents EAE by suppressing T cell proliferation and activation, with a potential for treatment of MS.
Users browsing this forum: No registered users